{"hands_on_practices": [{"introduction": "The entire ubiquitin-proteasome system is initiated by the fundamental activity of the E1 ubiquitin-activating enzyme. This exercise probes the core two-step chemical mechanism at the heart of the E1 enzyme: ATP-dependent adenylation followed by thioester formation. By analyzing the consequences of a specific mutation to the catalytic cysteine, you will dissect the precise chemical logic that \"charges\" a ubiquitin molecule, a prerequisite for all downstream events in the cascade [@problem_id:2966499].", "problem": "A ubiquitin-activating enzyme (E1) catalyzes the first two chemical steps of the ubiquitin conjugation cascade: activation of ubiquitin (Ub) by Adenosine Triphosphate (ATP) to form a ubiquitin–adenylate (Ub–AMP) and Inorganic Pyrophosphate (PPi), followed by formation of a high-energy E1~Ub thioester via nucleophilic attack by the enzyme’s catalytic cysteine on the Ub–AMP with release of adenosine monophosphate (AMP). The ubiquitin-conjugating enzyme (E2) is then charged by transthiolation from E1~Ub to the E2 catalytic cysteine to form E2~Ub, which is the donor for downstream ligation reactions catalyzed by ubiquitin ligases (E3).\n\nConsider a mutant E1 in which the catalytic cysteine is replaced by serine. You perform assays at saturating $[\\text{ATP}]$ and $[\\text{Ub}]$ that independently report the accumulation of E1-bound Ub–AMP and the formation of E2~Ub. Assume the following minimal kinetic scheme for the wild-type enzyme is a valid starting point:\n\n- Activation: $E1 + Ub + ATP \\xrightleftharpoons[k_{-1}]{k_{1}} E1\\cdot Ub\\text{-}AMP + PPi$\n- Thioester formation: $E1\\cdot Ub\\text{-}AMP \\xrightarrow{k_{2}} E1\\sim Ub + AMP$\n- Transthiolation to E2: $E1\\sim Ub + E2\\text{-}Cys \\xrightleftharpoons[k_{-3}]{k_{3}} E1 + E2\\sim Ub$\n\nHere $k_{1}$, $k_{-1}$, $k_{2}$, $k_{3}$, and $k_{-3}$ are microscopic rate constants, and $E1\\sim Ub$ and $E2\\sim Ub$ denote thioesters. No additional noncanonical pathways are significantly populated in the wild type under the assay conditions.\n\nFrom this mechanistic base, predict the biochemical consequences of replacing the catalytic cysteine with serine on (i) the steady-state accumulation of E1-bound Ub–AMP and (ii) the extent of E2 charging (E2~Ub formation). Choose the single best prediction.\n\nA. E1-bound Ub–AMP accumulates to a high level, and E2~Ub formation is negligible under the same conditions.\n\nB. E1-bound Ub–AMP decreases because the adenylate is destabilized, while partial E2~Ub still forms via transfer from an E1–Ub oxyester.\n\nC. E1-bound Ub–AMP is unchanged relative to wild type, and E2~Ub formation is unaffected because the adenylate directly charges E2.\n\nD. Free (dissociated) Ub–AMP accumulates in solution, and E2~Ub formation increases due to a higher effective concentration of activated ubiquitin available to E2.\n\nE. A transient increase in E1-bound Ub–AMP is followed by efficient E2 charging via formation of an isopeptide bond to a lysine on E2 that substitutes for the missing E1 cysteine.", "solution": "The problem statement is first subjected to validation.\n\n**Step 1: Extract Givens**\n- **Enzymes and substrates**: Ubiquitin-activating enzyme ($E1$), ubiquitin ($Ub$), Adenosine Triphosphate ($ATP$), ubiquitin-conjugating enzyme ($E2$).\n- **Intermediates and products**: Ubiquitin–adenylate ($Ub–AMP$), Inorganic Pyrophosphate ($PP_i$), Adenosine monophosphate ($AMP$), $E1 \\sim Ub$ (thioester), $E2 \\sim Ub$ (thioester).\n- **Mutation**: The catalytic cysteine ($Cys$) in $E1$ is replaced by serine ($Ser$).\n- **Assay conditions**: Saturating concentrations of $[ATP]$ and $[Ub]$.\n- **Observables**: (i) Steady-state accumulation of $E1$-bound $Ub–AMP$; (ii) extent of $E2$ charging ($E2\\sim Ub$ formation).\n- **Wild-type kinetic scheme**:\n    1.  Activation: $E1 + Ub + ATP \\xrightleftharpoons[k_{-1}]{k_{1}} E1\\cdot Ub\\text{-}AMP + PPi$\n    2.  Thioester formation: $E1\\cdot Ub\\text{-}AMP \\xrightarrow{k_{2}} E1\\sim Ub + AMP$\n    3.  Transthiolation to E2: $E1\\sim Ub + E2\\text{-}Cys \\xrightleftharpoons[k_{-3}]{k_{3}} E1 + E2\\sim Ub$\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding**: The problem is scientifically sound. It describes the accepted two-step mechanism for ubiquitin activation by $E1$ (adenylation followed by thioester formation) and the subsequent transfer to $E2$. The use of a cysteine-to-serine mutation is a standard biochemical technique to investigate the function of a catalytic thiol group.\n- **Well-Posedness**: The problem is well-posed. It presents a clear biochemical system, a specific perturbation (the mutation), and asks for predictable consequences on measurable quantities. A unique solution can be derived from first principles of enzyme kinetics and chemical reactivity.\n- **Objectivity**: The problem is stated in precise, objective language without ambiguity or subjective elements.\n- **Completeness and Consistency**: The problem provides a sufficient and consistent set of information to arrive at a conclusion. The provided kinetic scheme is a standard, simplified model of the process.\n\n**Step 3: Verdict and Action**\nThe problem statement is **valid**. A solution will be derived.\n\n**Derivation of the Solution**\n\nThe problem requires an analysis of how a Cysteine to Serine mutation in the catalytic site of the $E1$ enzyme affects the ubiquitin conjugation cascade. We analyze the process step-by-step based on the provided kinetic scheme.\n\n1.  **Analysis of the Wild-Type (WT) Pathway:**\n    -   Step $1$: Activation. $E1$ catalyzes the ATP-dependent adenylation of the C-terminus of $Ub$ to form a high-energy mixed anhydride intermediate, $Ub–AMP$, which remains bound to the enzyme as $E1\\cdot Ub\\text{-}AMP$. This reaction is reversible.\n    -   Step $2$: Thioester formation. The thiol group ($-SH$) of the catalytic cysteine in $E1$ acts as a nucleophile, attacking the carbonyl carbon of the ubiquitin in the bound $Ub–AMP$ intermediate. This forms a high-energy thioester bond ($E1\\sim Ub$) and releases $AMP$. The rate of this step is governed by the rate constant $k_2$.\n    -   Step $3$: Transthiolation. The charged $E1$ enzyme ($E1\\sim Ub$) serves as the donor to charge an $E2$ enzyme via a similar nucleophilic attack by the catalytic cysteine of $E2$, forming $E2\\sim Ub$.\n\n2.  **Analysis of the Mutant ($Cys \\to Ser$) Pathway:**\n    -   **Impact on Step 1 (Activation):** The catalytic cysteine is not directly involved in the adenylation reaction (binding of $ATP$ and $Ub$ and formation of $Ub-AMP$). Therefore, the mutant enzyme, let us call it $E1^{Ser}$, is expected to catalyze the formation of the $E1^{Ser}\\cdot Ub\\text{-}AMP$ intermediate, similar to the wild-type enzyme. Since the assay is performed at saturating $[ATP]$ and $[Ub]$, this first step will proceed to generate the enzyme-bound adenylate.\n    -   **Impact on Step 2 (Thioester formation):** This is the critical step affected by the mutation. In the WT enzyme, the nucleophile is the thiol group of cysteine. In the mutant, the nucleophile is the hydroxyl group ($-OH$) of serine. The sulfur atom in a thiol is a better nucleophile than the oxygen atom in a hydroxyl group. Furthermore, the $pK_a$ of a cysteine's thiol group is typically around $8-9$, allowing for a significant population of the highly nucleophilic thiolate anion ($-S^−$) at physiological $pH$. In contrast, the $pK_a$ of a serine's hydroxyl group is much higher (around $16-18$), meaning it exists almost exclusively in the less nucleophilic protonated form ($-OH$) at physiological $pH$. Consequently, the nucleophilic attack by serine's hydroxyl on the $Ub-AMP$ intermediate will be drastically slower than the attack by cysteine's thiol. The rate constant for this step in the mutant, $k_{2}^{mut}$, will be several orders of magnitude smaller than the wild-type rate constant $k_2$ ($k_{2}^{mut} \\ll k_2$).\n    -   **Impact on Step 3 (Transthiolation):** This step requires the product of step $2$, which is $E1\\sim Ub$. Since the formation of the covalent E1-ubiquitin adduct is severely impaired in the mutant (i.e., step $2$ is effectively blocked), the concentration of the required substrate for step $3$ will be negligible.\n\n3.  **Predicted Consequences:**\n    -   **(i) Steady-state accumulation of E1-bound Ub–AMP:** In any linear reaction pathway, if a step is blocked, the intermediate immediately preceding the block will accumulate. Here, step $2$ (consumption of $E1\\cdot Ub\\text{-}AMP$) is blocked, while step $1$ (formation of $E1\\cdot Ub\\text{-}AMP$) remains active. This kinetic \"trap\" will cause the $E1\\cdot Ub\\text{-}AMP$ intermediate to accumulate to a high steady-state level, limited only by the reverse reaction of step $1$ or dissociation from the enzyme.\n    -   **(ii) Extent of E2 charging (E2~Ub formation):** The formation of $E2\\sim Ub$ is dependent on the prior formation of $E1\\sim Ub$. Since the formation of $E1\\sim Ub$ is negligible in the mutant, the subsequent transfer of $Ub$ to $E2$ cannot occur. Therefore, the formation of $E2\\sim Ub$ will be negligible or completely abolished.\n\n**Option-by-Option Analysis**\n\n-   **A. E1-bound Ub–AMP accumulates to a high level, and E2~Ub formation is negligible under the same conditions.**\n    This statement aligns perfectly with our derived predictions. The blockage of the thioester formation step causes the upstream intermediate ($E1\\cdot Ub\\text{-}AMP$) to pile up, and the lack of the thioester donor prevents any downstream reaction, including E2 charging.\n    **Verdict: Correct.**\n\n-   **B. E1-bound Ub–AMP decreases because the adenylate is destabilized, while partial E2~Ub still forms via transfer from an E1–Ub oxyester.**\n    The premise that $E1\\cdot Ub\\text{-}AMP$ decreases is incorrect; a kinetic block leads to accumulation, not depletion. There is no reason to assume the mutation destabilizes the non-covalent binding of the adenylate. While an oxyester might form at an extremely slow rate, calling the resulting E2 charging \"partial\" is misleading, as the efficiency would be drastically reduced compared to wild-type, rendering it negligible for practical purposes.\n    **Verdict: Incorrect.**\n\n-   **C. E1-bound Ub–AMP is unchanged relative to wild type, and E2~Ub formation is unaffected because the adenylate directly charges E2.**\n    The level of the intermediate will not be unchanged; it will increase significantly. Furthermore, the claim that the adenylate directly charges E2 proposes a non-canonical mechanism that bypasses the known requirement for the $E1\\sim Ub$ thioester intermediate. This contradicts the provided reaction scheme.\n    **Verdict: Incorrect.**\n\n-   **D. Free (dissociated) Ub–AMP accumulates in solution, and E2~Ub formation increases due to a higher effective concentration of activated ubiquitin available to E2.**\n    The primary accumulation occurs for the enzyme-bound species, $E1\\cdot Ub\\text{-}AMP$. The notion that $E2\\sim Ub$ formation *increases* is nonsensical, as the catalytic pathway is fundamentally broken. Free $Ub-AMP$ is not the substrate for E2 charging.\n    **Verdict: Incorrect.**\n\n-   **E. A transient increase in E1-bound Ub–AMP is followed by efficient E2 charging via formation of an isopeptide bond to a lysine on E2 that substitutes for the missing E1 cysteine.**\n    This option correctly predicts an increase in $E1\\cdot Ub\\text{-}AMP$ but then posits a speculative and biochemically unsupported rescue mechanism. The formation of an isopeptide bond is the function of E3 ligases, not a promiscuous side reaction in the E1-E2 transfer step. There is no basis to assume such a reaction would occur, let alone be \"efficient\".\n    **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2966499"}, {"introduction": "Once activated, ubiquitin molecules are assembled into chains on target proteins, but not all chains are created equal. The specific linkage between ubiquitin moieties acts as a code that dictates the substrate's fate. This practice explores the critical role of Lysine 48-linked polyubiquitin chains, the canonical signal for proteasomal degradation. Through a well-designed thought experiment, you will explore why this specific linkage is paramount for degradation, thereby solidifying your understanding of the \"ubiquitin code\" that ensures cellular signals are interpreted correctly [@problem_id:2065628].", "problem": "In a hypothetical cell line, a genetic modification has been introduced such that the gene for ubiquitin is altered. The modified gene exclusively produces a mutant form of ubiquitin where the lysine residue at position 48 has been replaced with an arginine residue (this is often denoted as a K48R mutation). All other cellular machinery, including the ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), ubiquitin ligases (E3), and the proteasome complex, remain in their normal, functional forms. Assuming this cell line can survive, what would be the most significant and direct consequence on the process of protein degradation?\n\nA. The initial attachment of a single ubiquitin molecule to target proteins will be completely blocked.\n\nB. Target proteins will still be marked for degradation but will be processed by lysosomes instead of the proteasome.\n\nC. The formation of polyubiquitin chains required for proteasomal recognition will be severely impaired, leading to a decrease in the degradation of most cellular proteins.\n\nD. The activity of the E3 ubiquitin ligases will be allosterically inhibited by the mutant ubiquitin, preventing them from recognizing target proteins.\n\nE. The proteasome will degrade proteins at a much faster rate because the K48R ubiquitin is a stronger binding signal.", "solution": "The key biochemical principles are:\n- Ubiquitin is conjugated to substrate lysines through an isopeptide bond between the substrate lysine $\\epsilon$-amino group and the C-terminal carboxylate of ubiquitin at Gly76. This monoubiquitination step depends on E1, E2, and E3 enzymes and the integrity of ubiquitin’s Gly76, not on ubiquitin’s Lys48.\n- Polyubiquitin chain elongation requires that a lysine on a conjugated ubiquitin serves as the acceptor for the next ubiquitin’s Gly76, forming a specific isopeptide linkage. For proteasomal degradation, the canonical and most prevalent signal is a Lys48-linked polyubiquitin chain, typically of length at least four ubiquitins.\n- Lysine can form isopeptide bonds via its primary $\\epsilon$-amino group; arginine’s guanidinium group cannot serve as an acceptor for forming the same isopeptide linkage. Therefore, replacing Lys48 with Arg (K48R) abolishes the ability to form Lys48-linked chains.\n\nStep-by-step reasoning:\n1) Initial conjugation (monoubiquitination) remains possible: E1 activates ubiquitin via Gly76 adenylation and thioester formation, E2 carries ubiquitin as a thioester, and E3 ligates ubiquitin to a substrate lysine through the substrate’s $\\epsilon$-amino group and ubiquitin’s Gly76. Since the mutation is at Lys48 of ubiquitin (not at Gly76), and E1/E2/E3 are normal, the initial attachment of a single ubiquitin molecule is not blocked.\n\n2) Chain elongation at Lys48 is blocked: To build a Lys48-linked chain, the next ubiquitin must form an isopeptide bond between its Gly76 and the $\\epsilon$-amino group of Lys48 on the previously attached ubiquitin. The K48R mutation removes the necessary lysine acceptor at position 48 on every ubiquitin, so Lys48 linkages cannot be formed anywhere within the chain.\n\n3) Consequence for proteasomal targeting: The 26S proteasome most efficiently recognizes and degrades proteins tagged with Lys48-linked polyubiquitin chains (commonly requiring chains of length at least four). Without the ability to form Lys48 linkages, canonical proteasomal targeting is severely impaired. While other linkages (e.g., Lys11, Lys29, Lys63) remain chemically possible because those lysines are intact, and some E2/E3s can build non-Lys48 chains, these are generally not the dominant proteasome-targeting signals for most substrates. Thus, the most direct and significant outcome is a marked reduction in proteasome-mediated degradation of the majority of substrates.\n\nEvaluation of options:\n- A is incorrect: Initial monoubiquitination uses ubiquitin’s Gly76 and is not dependent on Lys48.\n- B is incorrect: There is no general redirection of most cytosolic proteins to lysosomes; K63-linked chains can mediate endocytic trafficking of membrane proteins, but this is not a wholesale replacement of proteasomal degradation.\n- D is incorrect: The mutation does not allosterically inhibit E3s; it removes a specific acceptor lysine on ubiquitin.\n- E is incorrect: Loss of Lys48 linkages removes the strongest proteasomal tag; it does not accelerate degradation.\n\nTherefore, the most significant and direct consequence is the severe impairment of Lys48-linked polyubiquitin chain formation and a consequent decrease in proteasomal degradation of most cellular proteins, matching option C.", "answer": "$$\\boxed{C}$$", "id": "2065628"}, {"introduction": "Protein stability is not a static property but a dynamic equilibrium maintained by a constant tug-of-war between ubiquitin ligases and deubiquitinases (DUBs). This exercise moves from individual enzymatic steps to the systems-level consequences of this dynamic balance. By modeling the effect of a competitive DUB inhibitor, you will apply principles of enzyme kinetics to calculate the resulting change in a protein's half-life, providing a quantitative appreciation for how cells fine-tune protein levels through the reversible nature of ubiquitination [@problem_id:2065622].", "problem": "A researcher is studying the stability of a transcription factor, TF-X. The protein's half-life is regulated by the ubiquitin-proteasome system. The interconversion between the unmodified form (TF-X) and the ubiquitinated form ($TF-X_{ub}$) can be modeled using first-order kinetics. The ubiquitination reaction, forming $TF-X_{ub}$ from TF-X, is characterized by a rate constant $k_{ub}$. The reverse reaction, catalyzed by a specific deubiquitinase (DUB), is characterized by a rate constant $k_{dub}$. Only the ubiquitinated form, $TF-X_{ub}$, is recognized and irreversibly degraded by the proteasome with a rate constant $k_{deg}$. In a normal cell, the system exists in a dynamic steady state where the ratio of the deubiquitination to ubiquitination rate constants is $k_{dub} / k_{ub} = 5$. Let the half-life of the total TF-X pool in this normal state be $T_0$.\n\nTo investigate the DUB's role, the researcher creates a cell line that stably expresses a catalytically inactive, dominant-negative mutant of the DUB, denoted DUB*. This mutant protein acts as a competitive inhibitor by binding to $TF-X_{ub}$ with an inhibition constant $K_I$, but it cannot process the substrate. The cellular concentration of DUB* is maintained at a level exactly three times its inhibition constant (i.e., [DUB*] = $3K_I$).\n\nAssuming the system reaches a new steady state in the presence of DUB*, calculate the ratio of the new half-life of the total TF-X pool ($T_{new}$) to its original half-life ($T_0$). Express your answer as an exact fraction in simplest form.", "solution": "Let $x(t)$ and $y(t)$ denote the concentrations of TF-X and $TF-X_{ub}$, respectively. The interconversion is first order: $X \\xrightleftharpoons[k_{dub}]{k_{ub}} X_{ub}$, and only $X_{ub}$ is irreversibly degraded at rate $k_{deg}$. Under the rapid interconversion (pre-equilibrium) assumption relative to degradation, the fraction of the total pool in the ubiquitinated form is determined by the reversible exchange:\n$$\np \\equiv \\frac{y}{x+y}=\\frac{k_{ub}}{k_{ub}+k_{dub}}.\n$$\nLet $N(t)=x(t)+y(t)$ be the total TF-X pool. Because only $y$ is degraded and $y=p\\,N$, the total evolves as a single first-order decay:\n$$\n\\frac{dN}{dt}=-k_{deg}\\,y=-k_{deg}\\,p\\,N,\n$$\nso the effective first-order decay constant for the total pool is $k_{deg}p$, and the half-life is\n$$\nT=\\frac{\\ln 2}{k_{deg}p}.\n$$\n\nNormal state. Given $k_{dub}/k_{ub}=5$, we have\n$$\np_{0}=\\frac{k_{ub}}{k_{ub}+k_{dub}}=\\frac{1}{1+\\frac{k_{dub}}{k_{ub}}}=\\frac{1}{1+5}=\\frac{1}{6},\n$$\nso\n$$\nT_{0}=\\frac{\\ln 2}{k_{deg}\\,p_{0}}=\\frac{6\\ln 2}{k_{deg}}.\n$$\n\nWith DUB*. A competitive inhibitor that binds $TF-X_{ub}$ with inhibition constant $K_{I}$ reduces the apparent deubiquitination rate constant by the factor $1+\\frac{[\\text{DUB}^*]}{K_{I}}$. Thus the effective rate constant is\n$$\nk_{dub}^{\\text{eff}}=\\frac{k_{dub}}{1+\\frac{[\\text{DUB}^*]}{K_{I}}}.\n$$\nWith $[\\text{DUB}^*]=3K_{I}$, this becomes\n$$\nk_{dub}^{\\text{eff}}=\\frac{k_{dub}}{4}.\n$$\nTherefore,\n$$\np_{\\text{new}}=\\frac{k_{ub}}{k_{ub}+k_{dub}^{\\text{eff}}}\n=\\frac{k_{ub}}{k_{ub}+\\frac{k_{dub}}{4}}\n=\\frac{1}{1+\\frac{k_{dub}}{4k_{ub}}}\n=\\frac{1}{1+\\frac{1}{4}\\cdot\\frac{k_{dub}}{k_{ub}}}\n=\\frac{1}{1+\\frac{5}{4}}=\\frac{4}{9},\n$$\nand\n$$\nT_{\\text{new}}=\\frac{\\ln 2}{k_{deg}\\,p_{\\text{new}}}=\\frac{9\\ln 2}{4k_{deg}}.\n$$\n\nTaking the ratio,\n$$\n\\frac{T_{\\text{new}}}{T_{0}}=\\frac{\\frac{9\\ln 2}{4k_{deg}}}{\\frac{6\\ln 2}{k_{deg}}}=\\frac{9/4}{6}=\\frac{9}{24}=\\frac{3}{8}.\n$$", "answer": "$$\\boxed{\\frac{3}{8}}$$", "id": "2065622"}]}